Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01497275 · ClinicalTrials.gov registry record · Phase 2
Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma
A Phase 2 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01497275 is a Phase 2 study that was terminated before completion, run by Duke University. The registered enrollment target is 5 participants.
The verdict
NCT01497275, a Phase 2 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects (good and bad) of the combination of ibritumomab tiuxetan (Zevalin) and bortezomib (Velcade) in patients with relapsed/refractory mantle cell lymphoma. Zevalin is a monoclonal antibody that is combined with a radioactive substance and given with another monoclonal antibody called rituximab (Rituxan). It works by attaching to cancer cells and releasing radiation to damage those cells. Both Zevalin and Rituxan are given in this study, along with Velcade.
Interventions
- DRUG Rituximab, Bortezomib,Y90 ibritumomab tiuxetan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2012-02 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01497275
The ClinicalTrials.gov registry entry for NCT01497275 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rituximab, Bortezomib,Y90 ibritumomab tiuxetan is the first listed.
NCT01497275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01497275 about?
NCT01497275 is a clinical study titled "Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma". The purpose of this study is to evaluate the effects (good and bad) of the combination of ibritumomab tiuxetan (Zevalin) and bortezomib (Velcade) in patients with relapsed/refractory mantle cell lymphoma. Zevalin is a monoclonal antibody that is combined with a radioactive substance and given with ...
What is the current status of trial NCT01497275?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2012-02. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01497275?
The interventions under investigation include: Rituximab, Bortezomib,Y90 ibritumomab tiuxetan (DRUG).
Who is sponsoring clinical trial NCT01497275?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.